Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 234 of 6351
-
New pill could outshine standard shot for tough breast cancer
Disease control Recruiting nowThis is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants w…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
AI takes on cancer radiotherapy: can a computer plan treatment in minutes?
Knowledge-focused OngoingThe aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (ou…
Sponsor: University College, London • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
New vaccine could stop recurring yeast infections in their tracks
Vaccine OngoingIn this study, the pentavalent bioconjugate candidate vaccine (Candi5V) against Candida will be tested to obtain first-time-in-human (FTIH) data on its safety, immunogenicity, and preliminary efficacy in women with recurrent vulvovaginal candidiasis.
Phase 1/2 • Sponsor: LimmaTech Biologics AG • Aim: Vaccine
Last updated Jun 27, 2026 09:10 UTC
-
New hope for endometrial cancer: targeted drug takes on chemo in major trial
Disease control OngoingResearchers are looking for new ways to treat people with endometrial cancer (EC) who have previously received treatment with platinum based therapy (a type of chemotherapy) and immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. This clinical s…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat stomach cancers in Mid-Stage trial
Disease control OngoingThis phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease in patients with gastric or gastroesophageal juncti…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Smarter radiation for head & neck cancer: Biopsy-Guided treatment may spare patients from dry mouth
Disease control Recruiting nowRationale \| Elective neck irradiation is performed in head and neck cancer patients treated with definitive (chemo)radiotherapy. The aim is to eradicate nodal metastases that are not detectable by pretreatment imaging techniques. It is conceivable that personalized neck irradiat…
Phase 3 • Sponsor: Radboud University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for late-stage breast cancer patients with no other options
Disease control Recruiting nowThis is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (a…
Phase 3 • Sponsor: BriaCell Therapeutics Corporation • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug cocktail aims to stop smoldering myeloma in its tracks
Disease control Recruiting nowThe purpose of this study is to see whether combination treatment of Teclistamab and Daratumumab (Tel-Dara) or combination Talquetamab and Daratumumab (Tal-Dara) will delay the onset of multiple myeloma.
Phase 2 • Sponsor: Carl Ola Landgren, MD, PhD • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Which drug stops Post-Birth bleeding better? a Head-to-Head test
Prevention CompletedPostpartum hemorrhage (PPH) is an obstetric emergency, with an estimated incidence ranging from 2.8% to 7.9%. Recent studies indicate an increasing trend in the frequency of PPH.Although it is more commonly seen in developing countries, it remains a significant cause of maternal …
Phase 4 • Sponsor: Ankara Etlik City Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill plus injection tame a tough blood cancer?
Disease control Recruiting nowAcute myeloid leukemia (AML) is a cancer of the blood and bone marrow and is the most common acute leukemia in adults. This study will evaluate how well venetoclax in combination with azacitidine works to treat AML in adult participants in Colombia. Venetoclax in combination wit…
Sponsor: AbbVie • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Immunotherapy duo takes aim at tough pancreatic cancer before surgery
Disease control Recruiting nowThis is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a tailored Blood-Thinner combo prevent second heart attacks without causing bleeding?
Disease control Recruiting nowThe goal of this clinical trial is to compare short-term Triple Antithrombotic Therapy (DAPT + Rivaroxaban) followed by DAPT with standard DAPT in selected ACS patients with high ischemic risk. The main questions it aims to answer are: * Whether the intervention is effective in …
Phase 4 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug trial aims to shrink painful lymphatic growths in kids and adults
Disease control Recruiting nowThe main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
Phase 2/3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThe purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 activating gene alterations, including unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could TB treatment be cut from 6 months to 17 weeks?
Disease control OngoingThe purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as effective as a standard six-month regimen for treat…
Phase 2/3 • Sponsor: Centers for Disease Control and Prevention • Aim: Disease control
Last updated Jun 26, 2026 18:57 UTC
-
New biologic drug aims to clear stubborn eczema in just 24 weeks
Disease control CompletedThe main purpose of this study is to evaluate the effectiveness of 24 weeks of lebrikizumab in improving disease severity, signs, and symptoms in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Can a standard blood thinner match a newer combo for preventing heart attacks?
Disease control Recruiting nowThe study aims to conduct a randomized controlled trial among adults aged 19 years or older who have experienced acute myocardial infarction at least one year prior, or who have other comorbidities such as peripheral arterial disease or multiple cardiovascular diseases, and have …
Phase 4 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a shot during pregnancy shield babies from RSV?
Vaccine CompletedThe purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.
Phase 2 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 13:07 UTC
-
Can a new drug boost radiation's power against head and neck cancer in older patients?
Disease control Stopped earlyThis is a multicenter, randomized, placebo-controlled, triple blind, phase II study to determine the efficacy and safety of xevinapant with radiotherapy in older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of oral cavity, oropharynx, hypopharyn…
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New targeted drug aims to outperform chemo in tough lung cancers
Disease control OngoingThe purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EG…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC